Back to Treatments

Treatment

Rifampicin (RIF) Monotherapy (4 months for Latent TB Infection)

1
Conditions
25
Trials
20K
Participants
68%
Average Safety

Condition Evidence

Drug-susceptible tuberculosis

25 trials · 20K participants

77% effectiveness · 68% safety
Rifampicin (RIF) Monotherapy (4 months for Latent TB Infection) | DFDA